Asian Scientist Magazine
Bristol-Myers Squibb Booked a New High
The Company offers products and experimental therapies to address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection and psychiatric disorders. Bristol-Myers Squibb is currently trading 0.71% versus ...
Bristol-Myers Squibb: Exec Insider and Fund Stock Sales in Q3
Bristol-Myers Squibb: 52-Week High Recently Eclipsed (BMY)